Premium
Monoclonal antibody proteomics: Discovery and prevalidation of chronic obstructive pulmonary disease biomarkers in a single step
Author(s) -
Csanky Eszter,
Olivova Petra,
Rajnavolgyi Eva,
Hempel William,
Tardieu Nadege,
Katalin Elesne Toth,
Jullien Anne,
MalderezBloes Carole,
Kuras Mariana,
Duval Manuel X.,
Nagy Laszlo,
Scholtz Beata,
Hancock William,
Karger Barry,
Guttman András,
Takacs Laszlo
Publication year - 2007
Publication title -
electrophoresis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.666
H-Index - 158
eISSN - 1522-2683
pISSN - 0173-0835
DOI - 10.1002/elps.200700256
Subject(s) - biomarker discovery , biomarker , proteomics , computational biology , drug discovery , monoclonal antibody , disease , bioinformatics , medicine , biology , antibody , immunology , genetics , gene
We define mAb proteomics as the global generation of disease specific antibodies that permit mass screening of biomarkers. An integrated, high‐throughput, disease‐specific mAb‐based biomarker discovery platform has been developed. The approach readily provided new biomarker leads with the focus on large‐scale discovery and production of mAb‐based, disease‐specific clinical assay candidates. The outcome of the biomarker discovery process was a highly specific and sensitive assay, applicable for testing of clinical validation paradigms, like response to treatment or correlation with other clinical parameters. In contrast to MS‐based or systems biology‐based strategies, our process produced prevalidated clinical assays as the outcome of the discovery process. By re‐engineering the biomarker discovery paradigm, the encouraging results presented in this paper clearly demonstrate the efficiency of the mAb proteomics approach, and set the grounds for the next steps of studies, namely, the hunt for candidate biomarkers that respond to drug treatment.